Protocol Overview
Synergy & Mechanism
TB-500 Mechanism
TB-500 is a fragment of Thymosin Beta-4 that promotes systemic healing through actin sequestration (enabling cellular migration), anti-inflammatory signaling, and angiogenesis. Unlike BPC-157 which excels locally, TB-500 provides whole-body healing support. It allows immune and repair cells to migrate efficiently to damaged sites.
Thymosin Alpha-1 Synergy
TA1 is the master regulator of adaptive immunity, maturing T-cells in the thymus, activating NK cells, and enhancing dendritic cell antigen presentation. During healing, proper immune function prevents opportunistic infections and coordinates the inflammatory-to-resolution transition. TA1 ensures TB-500 healing occurs in an optimally functioning immune environment.
Combined Dosing Protocol
Standard
TB-500 750mcg 3x/week
TA1 1.6mg 2x/week
TB: M/W/F, TA1: Tu/Th
8-12 weeks
Loading
TB-500 2mg 2x/week (wk1-4) then 750mcg
TA1 1.6mg 3x/week
Alternating days
12 weeks
Maintenance
TB-500 750mcg 2x/week
TA1 1.6mg 1x/week
M/Th
Ongoing
Reconstitution & Preparation
TB-500 Preparation
TB-500 vial: typically 5mg or 10mg lyophilized
5mg vial: reconstitute with 2mL BAC water = 2,500mcg/mL
750mcg dose = 30 units on insulin syringe
Refrigerate, use within 30 days
Thymosin Alpha-1 Preparation
TA1 vial: 1.6mg or 3.2mg lyophilized
1.6mg vial: reconstitute with 1mL BAC water
Use entire vial per dose (1.6mg)
Refrigerate, use within 14 days
Stacking Schedule (AM/PM Timing)
AM Protocol
Mon/Wed/Fri: TB-500 750mcg SubQ, abdomen
Tue/Thu: TA1 1.6mg SubQ, abdomen
Alternate compounds to spread injections
Morning dosing preferred
PM Protocol
No PM injections needed for standard protocol
Both can be taken any time of day
Some prefer TA1 in evening for overnight immune support
Rest days: Saturday and Sunday
Expected Timeline
Side Effects & Monitoring
Common Side Effects
Injection site redness (mild)
Mild fatigue during first week (immune activation)
Headache (uncommon)
Flu-like symptoms (TA1, first doses, indicates immune activation)
Precautions
TA1 may flare autoimmune conditions temporarily
Immunosuppressive therapy patients should consult physician
TB-500: avoid if active cancer (angiogenesis concern)
Monitor for immune over-activation signs
Blood Work Recommendations
Immune Panel
CD4/CD8 ratio, NK cell count, lymphocyte subsets
Baseline, Week 6, Week 12
Inflammatory
CRP, ESR, IL-6
Baseline, Week 4, Week 8
Basic
CBC with differential, CMP
Baseline, Week 6
Immune panels should show CD4/CD8 ratio normalization and NK cell count increases. CRP should decrease with TB-500.
Related Protocols & Tools